Antoine Yver
Equibles does not estimate personal net worth.
About Antoine Yver
Antoine Yver was last confirmed as Chairman at Centessa Pharmaceuticals plc (CNTA) in a filing dated May 15, 2023. The proxy statement of Centessa Pharmaceuticals plc reports total compensation of $1,380,739 for Antoine Yver in fiscal 2023, including a base salary of $538,200. Disclosed compensation is on record for 4 fiscal years.
Affiliation history
-
Start not stated–2023-05-15
Last confirmed by a filing; no departure on record
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Centessa Pharmaceuticals plc (CNTA) | M.D., M.Sc. Chairman of Development | $538,200 | $1,380,739 |
| 2022 | Centessa Pharmaceuticals plc (CNTA) | M.D., M.Sc. Chairman of Development | $517,500 | $2,517,232 |
| 2021 | Centessa Pharmaceuticals plc (CNTA) | M.D., M.Sc. Executive Vice President andChairman of Development | $312,500 | $17,127,519 |
| 2020 | Centessa Pharmaceuticals plc (CNTA) | M.D., M.Sc. Executive Vice President andChairman of Development | — | — |
Recent activity
No call appearances or filed executive changes recorded yet.